'6 choose 4': A framework to understand and facilitate discussion of strategies for overall survival safety monitoring

Authors: Yung, Godwin, Rufibach, Kaspar, Wolbers, Marcel, Yan, Mark, Wang, Jue

Subject Terms: Statistics - Methodology, Statistics - Applications

Access URL: http://arxiv.org/abs/2410.04020

Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti–PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia

Authors: Daver, Naval, Jonas, Brian A., Medeiros, Bruno C., Patil, Upen, Yan, Mark

Source: Leukemia & lymphoma. 63(11):2711-2714

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100192736822.0x000001&indx=1&recIds=ETOCvdc_100192736822.0x000001

A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia

Authors: Prebet, Thomas, Goldberg, Aaron D., Jurcic, Joseph G., Khaled, Samer, Dail, Monique, Feng, Yuning, Green, Cherie, Li, Chunze, Ma, Connie, Medeiros, Bruno C., Yan, Mark, Grunwald, Michael R.

Source: Leukemia & lymphoma. 63(9):2180-2188

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100165611346.0x000001&indx=1&recIds=ETOCvdc_100165611346.0x000001

Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome

Authors: Gerds, Aaron T. ^*, Scott, Bart L., Greenberg, Peter, Lin, Tara L., Pollyea, Daniel A., Verma, Amit, Dail, Monique, Feng, Yuning, Green, Cherie, Ma, Connie, Medeiros, Bruno C., Yan, Mark, Yousefi, Kasra, Donnellan, William

Source: In Blood Advances 22 February 2022 6(4):1152-1161

Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort

Authors: Dziadziuszko, Rafal, Mok, Tony, Peters, Solange, Han, Ji-Youn, Alatorre-Alexander, Jorge, Leighl, Natasha, Sriuranpong, Virote, Pérol, Maurice, de Castro Junior, Gilberto, Nadal, Ernest, de Marinis, Filippo, Frontera, Osvaldo Arén, Tan, Daniel S.W., Lee, Dae Ho, Kim, Hye Ryun, Yan, Mark, Riehl, Todd, Schleifman, Erica, Paul, Sarah M., Mocci, Simonetta, Patel, Rajesh, Assaf, Zoe June, Shames, David S., Mathisen, Michael S., Gadgeel, Shirish M.

Source: In Journal of Thoracic Oncology December 2021 16(12):2040-2050

Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study

Authors: Tilly, Hervé, Morschhauser, Franck, Bartlett, Nancy L, Mehta, Amitkumar, Salles, Gilles, Haioun, Corinne, Munoz, Javier, Chen, Andy I, Kolibaba, Kathryn, Lu, Dan, Yan, Mark, Penuel, Elicia, Hirata, Jamie, Lee, Calvin, Sharman, Jeff P

Source: In The Lancet Oncology July 2019 20(7):998-1010

Influencing Participant Behavior Through a Notification-Based Recommendation System
Persuasive technology (International conference)

Authors: Reddy, Venkata, Bushree, Brian, Chong, Marcus, Law, Matthew, Thirani, Mayank, Yan, Mark, Rollins, Sami, Banerjee, Nilanjan, Joshi, Alark

Source: Lecture notes in computer science. 10809:113-119

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCCN603477910&indx=1&recIds=ETOCCN603477910

ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study

Authors: Flowers, Christopher ¹, Tilly, Hervé ², Morschhauser, Franck ³, Sehn, Laurie H. ⁴, Friedberg, Jonathan W. ⁵, Trněný, Marek ⁶, Sharman, Jeff P. ⁷, Herbaux, Charles ⁸, Burke, John M. ⁹, Matasar, Matthew ¹⁰, Rai, Shinya ¹¹, Izutsu, Koji ¹², Mehta-Shah, Neha ¹³, Oberic, Lucie ¹⁴, Chauchet, Adrien ¹⁵, Jurczak, Wojciech ¹⁶, Song, Yuqin ¹⁷, Greil, Richard ¹⁸, Mykhalska, Larysa ¹⁹, Bergua-Burgués, Juan Miguel ²⁰, Cheung, Matthew C. ²¹, Pinto, Antonio ²², Shin, Ho-Jin ²³, Hapgood, Greg ²⁴, Munhoz, Eduardo ²⁵, Abrisqueta, Pau ²⁶, Gau, Jyh-Pyng ²⁷, Hirata, Jamie ²⁸, Jiang, Yanwen ²⁸, Yan, Mark ²⁹, Lee, Calvin ²⁸, Salles, Gilles ³⁰

Source: In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S358-S359

Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study

Authors: Friedberg, Jonathan W., Thompson, Carrie A., Trněný, Marek, Morschhauser, Franck ^*, Salles, Gilles, Reagan, Patrick M., Hertzberg, Mark ^*, Smolewski, Piotr ^*, Zhang, Huilai ^*, Thieblemont, Catherine, Hu, Bei, Fonseca, Gustavo ^*, Kim, Won-Seog ^*, Martelli, Maurizio ^*, Mehta, Amitkumar ^*, Campinha-Bacote, Avrita ^*, Yan, Mark ^*, Hirata, Jamie, Sugidono, Matthew, Lee, Calvin, Sharman, Jeff P.

Source: In Blood 15 November 2022 140 Supplement 1:6623-6626

Life and understanding:the origins of ‘understanding’ in self-organizing nervous systems.

Authors: Yan Mark Yufik, Karl Friston

Source: Frontiers in Systems Neuroscience, Vol 10 (2016)

Subject Terms: Consciousness, GRASP, understanding, Variational free energy, Thermodynamic free energy, neuronal packets, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571

File Description: electronic resource

Relation: http://journal.frontiersin.org/Journal/10.3389/fnsys.2016.00098/full; https://doaj.org/toc/1662-5137

Access URL: https://doaj.org/article/0709ca6b7d184d5dab4fd82d9b8eff01

Oral Abstract: ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study

Authors: Flowers, Christopher, Tilly, Hervé, Morschhauser, Franck, Sehn, Laurie H., Friedberg, Jonathan W., Trněný, Marek, Sharman, Jeff P., Herbaux, Charles, Burke, John M., Matasar, Matthew, Rai, Shinya, Izutsu, Koji, Mehta-Shah, Neha, Oberic, Lucie, Chauchet, Adrien, Jurczak, Wojciech, Song, Yuqin, Greil, Richard, Mykhalska, Larysa, Bergua-Burgués, Juan Miguel, Cheung, Matthew C., Pinto, Antonio, Shin, Ho-Jin, Hapgood, Greg, Munhoz, Eduardo, Abrisqueta, Pau, Gau, Jyh-Pyng, Hirata, Jamie, Jiang, Yanwen, Yan, Mark, Lee, Calvin, Salles, Gilles

Source: Clinical lymphoma, myeloma & leukemia. 22(S2):S117-S117

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100172886070.0x000001&indx=1&recIds=ETOCvdc_100172886070.0x000001

Poster: ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study

Authors: Flowers, Christopher, Tilly, Hervé, Morschhauser, Franck, Sehn, Laurie H., Friedberg, Jonathan W., Trněný, Marek, Sharman, Jeff P., Herbaux, Charles, Burke, John M., Matasar, Matthew, Rai, Shinya, Izutsu, Koji, Mehta-Shah, Neha, Oberic, Lucie, Chauchet, Adrien, Jurczak, Wojciech, Song, Yuqin, Greil, Richard, Mykhalska, Larysa, Bergua-Burgués, Juan Miguel, Cheung, Matthew C., Pinto, Antonio, Shin, Ho-Jin, Hapgood, Greg, Munhoz, Eduardo, Abrisqueta, Pau, Gau, Jyh-Pyng, Hirata, Jamie, Jiang, Yanwen, Yan, Mark, Lee, Calvin, Salles, Gilles

Source: Clinical lymphoma, myeloma & leukemia. 22(S2):S163-S163

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100172883911.0x000001&indx=1&recIds=ETOCvdc_100172883911.0x000001

Pola-R-CHP or R-CHOEP for first-line therapy of younger patients with high-risk diffuse large B-cell lymphoma: a retrospective comparison of two randomized phase 3 trials

Authors: Lenz, Georg, Tilly, Hervé, Ziepert, Marita, Altmann, Bettina, Herbaux, Charles, Frontzek, Fabian, Nickelsen, Maike, Lee, Calvin, Hirata, Jamie, Sahin, Deniz, Chohan, Saibah, Batlevi, Connie Lee, Yan, Mark, Morschhauser, Franck, Schmitz, Norbert

Source: Leukemia; 20240101, Issue: Preprints p1-3, 3p

Analysis of peripheral neuropathy in the POLARIX study using clinician- and patient-reported outcomes

Authors: Trněný, Marek, Fogliatto, Laura, Gardner, Faithlore, Flinn, Ian, Larouche, Jean-François, Haioun, Corinne, Canales, Miguel, Goto, Hideki, Hajek, Roman, Salles, Gilles, Campinha-Bacote, Avrita, Yan, Mark, Kothari, Rucha, Man, Gabriel, Sahin, Deniz, Hirata, Jamie, Lee, Calvin, Tilly, Hervé, Flowers, Christopher R.

Source: Blood Advances; 20250101, Issue: Preprints

Personalized multimedia display/digital TV for multi-tasking

Personalized multimedia display/digital TV for multi-tasking

CO43923: A Platform Study Evaluating the Safety and Efficacy of Multiple Treatment Combinations in Patients with Multiple Myeloma

Authors: Sheikh, Semira ^*, Patil, Upen ^*, Wehrman, Kristin ^*, Sideri, Elissavet ^*, Ruppert, Shannon M. ^*, Yu, Yanke ^*, Yan, Mark ^*, Bhatti, Jasdeep ^*, Pogeza, Lydia ^*, Nouet, Yann

Source: In Blood 15 November 2022 140 Supplement 1:12640-12641

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

Authors: Peters, Solange, Dziadziuszko, Rafal, Morabito, Alessandro, Felip, Enriqueta, Gadgeel, Shirish M., Cheema, Parneet, Cobo, Manuel, Andric, Zoran, Barrios, Carlos H., Yamaguchi, Masafumi, Dansin, Eric, Danchaivijitr, Pongwut, Johnson, Melissa, Novello, Silvia, Mathisen, Michael S., Shagan, Sarah M., Schleifman, Erica, Wang, Jin, Yan, Mark, Mocci, Simonetta, Voong, David, Fabrizio, David A., Shames, David S., Riehl, Todd, Gandara, David R., Mok, Tony

Source: Nature Medicine; September 2022, Vol. 28 Issue: 9 p1831-1839, 9p

The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Authors: Tilly, Hervé, Morschhauser, Franck, Sehn, Laurie H., Friedberg, Jonathan W., Trněný, Marek, Sharman, Jeff P., Herbaux, Charles, Burke, John M., Matasar, Matthew, Rai, Shinya, Izutsu, Koji, Mehta-Shah, Neha, Oberic, Lucie, Chauchet, Adrien, Jurczak, Wojciech, Song, Yuqin, Greil, Richard, Mykhalska, Larysa, Bergua Burgués, Juan Miguel, Cheung, Matthew C., Pinto, Antonio, Shin, Ho-Jin, Hapgood, Greg, Munhoz, Eduardo, Abrisqueta Costa, Pau, Gau, Jyh-Pyng, Hirata, Jamie, Jiang, Yanwen, Yan, Mark, Lee, Calvin, Flowers, Christopher R., Salles, Gilles

Source: In Blood 4 December 2021 138 Supplement 2

Lymphoma Microenvironment Deconvolution Links M1 Macrophage Infiltration to Clinical Outcome in Diffuse Large B-Cell Lymphoma

Authors: Yan, Mark ^*, Chang, Yi Meng ^*, Raghavan, Vibha ^*, Dong, Estella ^*, Klein, Christian, Nielsen, Tina G ^*, Paulson, Joseph N ^*, Hatzi, Katerina ^*

Source: In Blood 5 November 2020 136 Supplement 1:29-30